Referred to the House Committee on Energy and Commerce.
This bill (HOPE Act) amends section 1003 of the 21st Century Cures Act to clarify that certain State and Tribal grants for responding to opioid use disorder may be used to acquire, make available, and maintain public access opioid overdose reversal kits. It adds a statutory definition of “public access opioid overdose reversal kit” as a kit that includes opioid overdose reversal medication and instructions for administering it.
Supporters (liberal and centrist) emphasize immediate life-saving potential and alignment with public-health practice; conservatives emphasize moral hazard and federal overreach concerns.
Relative to its intended legislative type, this bill is a concise statutory amendment that clearly integrates into existing grant authority to permit specific uses of funds and adds a basic statutory definition.
This bill (HOPE Act) amends section 1003 of the 21st Century Cures Act to clarify that certain State and Tribal grants for responding to opioid use disorder may be used to acquire, make available, and maintain public access opioid overdose reversal kits.
It adds a statutory definition of “public access opioid overdose reversal kit” as a kit that includes opioid overdose reversal medication and instructions for administering it.
The amendments rearrange a few technical paragraphs in the statute and explicitly list activities related to public access kits among allowable primary prevention activities funded by those grants.
Content-wise this is a modest, administratively focused change with low fiscal impact and clear public-health intent, characteristics that generally improve a bill's prospects. Still, the subject touches on harm-reduction policy that can attract opposition, and the bill lacks compromise features (sunsets, pilots) that might reduce objections. Procedural barriers in the Senate also temper chances unless the text is folded into a larger, bipartisan opioid package or must-pass vehicle.
Relative to its intended legislative type, this bill is a concise statutory amendment that clearly integrates into existing grant authority to permit specific uses of funds and adds a basic statutory definition. It leaves implementation mechanics, fiscal effects, standards, and accountability largely to the underlying program and administrative practice.
Supporters (liberal and centrist) emphasize immediate life-saving potential and alignment with public-health practice; conservatives emphasize moral hazard and federal overreach concerns.
These are examples from the analysis, not a ranked list of the most-affected groups.
Supporters (liberal and centrist) emphasize immediate life-saving potential and alignment with public-health practice; conservatives emphasize moral hazard and federal overreach concerns.
A mainstream liberal would likely view this bill positively as a targeted, evidence-based harm-reduction measure that expands life-saving resources into public settings and tribal communities.
They would see this as a modest, practical change to allow existing grant dollars to be used for naloxone-style kits and associated maintenance, consistent with public-health approaches to the overdose crisis.
They would likely want to ensure implementation prioritizes equity for disproportionately affected communities and tribal nations.
A centrist or moderate would probably view the bill as a narrowly targeted, pragmatic fix that clarifies allowable uses of existing grants to address a clear public-health problem.
They would appreciate that it does not create a large new entitlement and focuses on proven interventions, but would want clarity about costs, oversight, and whether additional appropriations are needed.
Overall, a centrist would be inclined to support it if paired with accountability measures.
A mainstream conservative would likely be skeptical of this bill, viewing it as an expansion of allowable federal grant activities toward harm-reduction measures they may see as enabling drug use.
They would focus on concerns about federal overreach into state and tribal policy choices, potential moral hazard, and the absence of explicit appropriations or accountability language.
Some conservatives might accept the measure if it is strictly optional for states/tribes and accompanied by safeguards and oversight.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content-wise this is a modest, administratively focused change with low fiscal impact and clear public-health intent, characteristics that generally improve a bill's prospects. Still, the subject touches on harm-reduction policy that can attract opposition, and the bill lacks compromise features (sunsets, pilots) that might reduce objections. Procedural barriers in the Senate also temper chances unless the text is folded into a larger, bipartisan opioid package or must-pass vehicle.
The bill has not accumulated any surfaced votes yet.
Supporters (liberal and centrist) emphasize immediate life-saving potential and alignment with public-health practice; conservatives emphas…
Content-wise this is a modest, administratively focused change with low fiscal impact and clear public-health intent, characteristics that…
Relative to its intended legislative type, this bill is a concise statutory amendment that clearly integrates into existing grant authority to permit specific uses of funds and adds a basic statutory definition. It leav…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.